Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues:
Total revenues	$ 0	$ 0	$ 235	$ 0
Revenue, Product and Service [Extensible Enumeration]	License and Collaboration Revenues [Member]	License and Collaboration Revenues [Member]	License and Collaboration Revenues [Member]	License and Collaboration Revenues [Member]
Operating expenses:
Research and development	$ 13,973	$ 9,840	$ 27,337	$ 19,219
General and administrative	3,342	3,718	6,849	7,126
Total operating expenses	17,315	13,558	34,186	26,345
Loss from operations	(17,315)	(13,558)	(33,951)	(26,345)
Total other income (expense), net	1,009	1,216	2,158	2,051
Consolidated net loss	(16,306)	(12,342)	(31,793)	(24,294)
Net (gain) loss attributable to noncontrolling interest in Pangu BioPharma Limited	0	4	(4)	5
Net loss attributable to aTyr Pharma, Inc.	$ (16,306)	$ (12,338)	$ (31,797)	$ (24,289)
Net loss per share - basic	$ (0.23)	$ (0.22)	$ (0.46)	$ (0.50)
Net loss per share - diluted	$ (0.23)	$ (0.22)	$ (0.46)	$ (0.50)
Shares used in computing net loss per share, basic	72,284,351	55,143,805	69,204,401	48,557,347
Shares used in computing net loss per share, diluted	72,284,351	55,143,805	69,204,401	48,557,347

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Name:	us-gaap_EarningsPerShareBasic
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.